Clinical Trial
Share your love
Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report
(Image Credit: AdobeStock/tadamichi) Sight Sciences announced that its TearCare System has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology.1,2 This marks the…
Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010
(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…
The state of retina at ASRS 2025 with Charles C. Wykoff, MD, PhD, and Kevin Quinn
(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…
EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease
(Image credit: AdobeStock/Pete) The European Medicines Agency (EMA) granted Orphan designations to MCO-010 (sonpiretigene isteparvovec) across 5 categories of retinal dystrophies. The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD). The EMA…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences – The Manila Times
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences The Manila Times Source: Author: | Date: 2025-09-01 08:15:00 Source: Author: | Date: 2025-09-01 08:15:00
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences – Yahoo Finance
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences Yahoo Finance Source: Author: | Date: 2025-09-01 08:00:00 Source: Author: | Date: 2025-09-01 08:00:00
Regenerons $0.33 Billion Trading Day 287th in Activity as Sepsis Trial Advances and Eylea HD Approval Drive Mixed Investor Signals – AInvest
Regenerons $0.33 Billion Trading Day 287th in Activity as Sepsis Trial Advances and Eylea HD Approval Drive Mixed Investor Signals AInvest Source: Author: | Date: 2025-08-29 23:47:00 Source: Author: | Date: 2025-08-29 23:47:00
A study of the progression of sensitivity loss in GA over time using inferred data
(Image Credit: AdobeStock) The recent OMEGA study1 found that “inferred sensitivity” mapping may be a potential functional surrogate end point for geographic atrophy (GA) based on its ability to predict retinal function with high spatial resolution and without extensive psychophysical…
FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The recent CRL included only 1 deficiency, for…
Study finds value in home OCT monitoring
(Image credit: AdobeStock/Pixel-Shot) A study published in Ophthalmology Science shows that by analyzing up-to daily home OCT images, artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD). This may allow physicians to manage…